Chronic lymphocytic leukemia prognostic models in real life: still a long way off

Figures & data

Table 1. Characteristics of prognostic models in CLL with at least 3 validation studies and overall survival as endpoint

Prognostic model	Variables	Endpoint analyzed	Number of patients included in development and validation studies
2007 MDACC*^(1)	age, ALC, β2 m nodal groups Rai stage gender	Overall survival	7246
CLL-IPI^§(4)	age β2-m IGHV mutational status, Rai/Binet stage TP53 mutational status	Overall survival	6003
B-B°^(5)	IGHV mutational status, FISH cytogenetics del (11q) and/or del (17p)	Overall survival	2696
BALL^^ (7)	β2-m LDH Hemoglobin Time from initiation of last therapy <24 mo.	Overall survival	30

*2007 MDACC, MD Anderson Cancer Center

^§CLL-IPI, Chronic Lymphocytic Leukemia-International Prognostic Index

°B-B, Barcelona-Brno

^BALL, B₂-microglobulin, Anemia, LDH, Last therapy

Figure 1. Linear regression correlating the complexity of prognostic models with their discriminating power (i.e., the c-statistic). Complexity of models reflected the number of variables included. Models considered for the purpose of this analysis had overall survival (OS) as endpoint and at least three validation studies. Models fulfilling these criteria were 2007 MDACC, CLL-IPI, Barcelona-Brno, and BALL score [1,4,5,7]

Wierda WG, O’Brien S, Wang X, et al. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood. 2007;109(11):4679–4685.

 PubMed Web of Science ®Google Scholar

International CLL-IPI working group. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol. 2016;17(6):779–790.

 PubMed Web of Science ®Google Scholar

Delgado J, Doubek M, Baumann T, et al. Chronic lymphocytic leukemia: a prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI. Am J Hematol. 2017;92(4):375–380.

 PubMed Web of Science ®Google Scholar

Soumerai JD, Ni A, Darif M, et al. Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations. Lancet Haematol. 2019 Jul;6(7):e366–e374.

 PubMed Web of Science ®Google Scholar